403 related articles for article (PubMed ID: 31894895)
1. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
[TBL] [Abstract][Full Text] [Related]
2. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
3. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
5. Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer.
Chen R; Qian Z; Xu X; Zhang C; Niu Y; Wang Z; Sun J; Zhang X; Yu Y
Pharmacol Res; 2021 Mar; 165():105442. PubMed ID: 33497805
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
8. Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer.
Zhang Y; Li M; Hu C
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):457-464. PubMed ID: 30458987
[TBL] [Abstract][Full Text] [Related]
9. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L
Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557
[TBL] [Abstract][Full Text] [Related]
10. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
[TBL] [Abstract][Full Text] [Related]
12. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
14. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Fu Y; Zhang Y; Lei Z; Liu T; Cai T; Wang A; Du W; Zeng Y; Zhu J; Liu Z; Huang JA
J Hematol Oncol; 2020 Dec; 13(1):169. PubMed ID: 33287873
[TBL] [Abstract][Full Text] [Related]
15. RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.
Cho JH; You YM; Yeom YI; Lee DC; Kim BK; Won M; Cho BC; Kang M; Park S; Yang SJ; Kim JS; Kim JA; Park KC
Cell Death Dis; 2018 May; 9(6):587. PubMed ID: 29789542
[TBL] [Abstract][Full Text] [Related]
16. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
17. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
[TBL] [Abstract][Full Text] [Related]
18. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
19. miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1.
Zhang T; Wang N
Oncol Res; 2018 Sep; 26(8):1191-1200. PubMed ID: 29386087
[TBL] [Abstract][Full Text] [Related]
20. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]